Barrier Damage and The Immune CascadeNorthwestern University CounterACT Center of Excellence (NUCCX)
屏障损伤和免疫级联西北大学 CounterACT 卓越中心 (NUCCX)
基本信息
- 批准号:10682598
- 负责人:
- 金额:$ 268.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-17 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAnti-Inflammatory AgentsArtsBiological MarkersBurn injuryCOVID-19Chemical AgentsChicagoCholecalciferolClinicalClinical TrialsCommunicationCommunitiesComplexCorneaCutaneousData AnalysesDevelopmentDiseaseEducationEducational workshopEyeEye InjuriesEyedropsFosteringGoalsHealthHigh Density LipoproteinsHumanHybridsImmuneImmunologyInflammationInflammatoryInjuryInterdisciplinary StudyInvestigationKeratitisLate EffectsLibrariesLipidsMechlorethamineMediatingMelaninsMicroRNAsMustardMustard GasNamesNanotechnologyNewsletterPatient CarePatientsPeptidesPharmaceutical PreparationsPhasePolymersPositioning AttributePropertyRecording of previous eventsRegimenResearchResearch PersonnelResearch Project GrantsSamplingSchoolsScienceScientistServicesSkinSkin injurySocietiesSunburnSystemic TherapyTechnologyTestingTherapeutic UsesTopical applicationTraining and EducationTranslational ResearchTranslationsUniversitiesWomanarchived databoyschemical threatcollegedata archivediversity and inclusionefficacy evaluationeye drynessgirlsimmune activationimprovedin vivoinnovationmedical countermeasuremedical schoolsmultiple omicsnanolipoprotein particlesnanoparticlenonhuman primatenovelnovel therapeuticsoutreachparticleprogramsrecruitsynergismsystemic interventiontherapeutic developmenttranslational studywound healing
项目摘要
Northwestern University (NU) is recognized for its strong interdisciplinary cutaneous, ocular, nanotechnology
and immunology research programs with particular strength in investigations related to wound repair and
inflammation. Leveraging these strengths, the theme of the NU CounterAct Center of Excellence (NUCCX) is
the “Barrier Damage and The Immune Cascade”, with its goal to promote outstanding translational research in
the treatment of sulfur mustard (SM) injury. The NUCCX, with its 12 senior research scientists, encompasses 7
University departments within the Feinberg Medical School and the Weinberg College of Arts and Sciences.
Information generated through the NUCCX will improve patient care to those suffering from SM injury. To
accomplish this goal, the NUCCX has the following Research Projects and Cores: (i) Topical and Systemic
Interventions for Mustard-induced Skin Injury (Project 1); (ii) Reversing the Ocular Impact of NM and SM Through
Novel Therapies (Project 2); (iii) Translation and Trials: Advancing Medical Countermeasure Development
(Project 3); (iv) Administrative Core (Core A); (v) Lipid-Based Materials Synthesis and Characterization Core
(Core B); (vi) Polymeric Materials Synthesis and Characterization Core (Core C); and (vii) Education and
Enrichment Core (Core D). Project 1 will examine the clinical potential of systemically administered PLGA-IMPs
in conjunction with vitamin D3 to mitigate immune activation following NM and SM skin exposure. A similar
nanoparticle-based strategy will be used to evaluate reduction of skin inflammation with topical HDL NP and/or
synthetic melanin PDA NP. Project 2 will define the clinical potential of topical HDL NP-based eye drops in the
context of acute and delayed phases resulting from NM and SM exposure in the cornea. A similar approach will
be taken to evaluate systemically administered vitamin D3 and PLGA-IMPs in ocular NM/SM injury. Project 3
will use non-invasive testing in humans to define the signature inflammatory biomarkers that will be evaluated in
clinical trials testing of vitamin D3 and PLGA-IMP. The translational studies are highly relevant to mustard as
they are based on multi-omics analysis data of archived skin samples from in vivo SM (non-human primate) and
NM (human) mustard exposure. The Admin Core will be a focal point for all University-wide SM-related activities
and will be responsible for coordinating all activities of the NUCCX. Core B will synthesize a suite of organic
cores to be used as templates to produce a library of nanoparticles formulated to be topically applied to the eye
and skin. Core C will synthesize synthetic melanin, polymer-peptide hybrid materials and PLGA-IMPs to be used
for therapeutic development. Core D will foster education and training, as well as advance personal and
professional development of NUCCX trainees and investigators. This Core will also promote inclusivity and
diversity within the mustard injury field. Projects 1-3 and Cores A-D interdigitate with each other and have strong
translational components. The NUCCX is well positioned to take basic findings into a clinical setting, which will
facilitate our understanding and treating SM injury of the skin and eyes.
西北大学(NU)以其强大的跨学科皮肤,眼,纳米技术而闻名
和免疫学研究计划,在与伤口修复有关的研究方面具有特别的优势,
炎症利用这些优势,卓越的NU反行动中心(NUCCX)的主题是
“屏障损伤和免疫级联”,其目标是促进杰出的转化研究,
硫芥(SM)损伤的治疗。NUCCX拥有12名高级研究科学家,
Feinberg医学院和温伯格艺术与科学学院内的大学部门。
通过NUCCX生成的信息将改善SM损伤患者的护理。到
为了实现这一目标,NUCCX有以下研究项目和核心:(一)专题和系统
芥子气引起的皮肤损伤的干预措施(项目1);(ii)通过
新疗法(项目2);(iii)翻译和试验:推进医疗对策开发
(项目3);(四)行政核心(核心A);(五)脂基材料合成和表征核心
(Core B);(vi)聚合物材料合成和表征核心(核心C);以及(vii)教育和
浓缩核心(核心D)。项目1将检查全身给药PLGA-IMP的临床潜力
与维生素D3结合以减轻NM和SM皮肤暴露后的免疫激活。类似的
基于纳米颗粒的策略将用于评估局部HDL NP和/或
合成黑色素PDA NP。项目2将确定局部HDL NP滴眼液在美国的临床潜力。
角膜中NM和SM暴露导致的急性和延迟阶段的背景。类似的方法将
用于评价全身给予的维生素D3和PLGA-IMP在眼部NM/SM损伤中的作用。项目3
将在人体中使用非侵入性测试来定义将在临床上评估的标志性炎症生物标志物。
维生素D3和PLGA-IMP的临床试验测试。转化研究与芥末高度相关,
它们基于来自体内SM(非人灵长类动物)的存档皮肤样品的多组学分析数据,
NM(人类)芥子气暴露。行政核心将成为所有全校SM相关活动的焦点
并将负责协调NUCCX的所有活动。核心B将合成一套有机
用作模板以产生配制成局部施用到眼睛的纳米颗粒库的核
和皮肤。核心C将合成合成黑色素、聚合物-肽杂化材料和PLGA-IMP
用于治疗发展。核心D将促进教育和培训,并促进个人和
NUCCX学员和调查员的专业发展。该核心还将促进包容性,
芥末伤害领域的多样性。项目1-3和核心A-D相互交叉,
平移分量NUCCX能够很好地将基本发现应用于临床,
有助于我们对皮肤和眼睛SM损伤的认识和治疗。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vitamin D3 and deconvoluting a rash.
- DOI:10.1172/jci.insight.163789
- 发表时间:2023-01-24
- 期刊:
- 影响因子:8
- 作者:Ernst, Madison K.;Evans, Spencer T.;Techner, Jose-Marc;Rothbaum, Robert M.;Christensen, Luisa F.;Onay, Ummiye Venus;Biyashev, Dauren;Demczuk, Michael M.;Nguyen, Cuong V.;Honda, Kord S.;McCormick, Thomas S.;Tsoi, Lam C.;Gudjonsson, Johann E.;Cooper, Kevin D.;Lu, Kurt Q.
- 通讯作者:Lu, Kurt Q.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT M LAVKER其他文献
ROBERT M LAVKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT M LAVKER', 18)}}的其他基金
Reversing the ocular impact of NM and SM through novel therapies
通过新疗法扭转 NM 和 SM 对眼部的影响
- 批准号:
10282412 - 财政年份:2021
- 资助金额:
$ 268.38万 - 项目类别:
Reversing the ocular impact of NM and SM through novel therapies
通过新疗法扭转 NM 和 SM 对眼部的影响
- 批准号:
10682631 - 财政年份:2021
- 资助金额:
$ 268.38万 - 项目类别:
Barrier Damage and The Immune CascadeNorthwestern University CounterACT Center of Excellence (NUCCX)
屏障损伤和免疫级联西北大学 CounterACT 卓越中心 (NUCCX)
- 批准号:
10282406 - 财政年份:2021
- 资助金额:
$ 268.38万 - 项目类别:
Reversing the ocular impact of NM and SM through novel therapies
通过新疗法扭转 NM 和 SM 对眼部的影响
- 批准号:
10490420 - 财政年份:2021
- 资助金额:
$ 268.38万 - 项目类别:
Barrier Damage and The Immune CascadeNorthwestern University CounterACT Center of Excellence (NUCCX)
屏障损伤和免疫级联西北大学 CounterACT 卓越中心 (NUCCX)
- 批准号:
10490379 - 财政年份:2021
- 资助金额:
$ 268.38万 - 项目类别:
The Roles of Autophagy in Limbal/Corneal Epithelia.
自噬在角膜缘/角膜上皮中的作用。
- 批准号:
10225304 - 财政年份:2018
- 资助金额:
$ 268.38万 - 项目类别:
The Roles of Autophagy in Limbal/Corneal Epithelia.
自噬在角膜缘/角膜上皮中的作用。
- 批准号:
10400950 - 财政年份:2018
- 资助金额:
$ 268.38万 - 项目类别:
The Roles of Autophagy in Limbal/Corneal Epithelia.
自噬在角膜缘/角膜上皮中的作用。
- 批准号:
9910410 - 财政年份:2018
- 资助金额:
$ 268.38万 - 项目类别:
2016 Cornea, Biology and Pathobiology Gordon Research Conference & Gordon Research Seminar
2016年角膜、生物学和病理学戈登研究会议
- 批准号:
9052308 - 财政年份:2015
- 资助金额:
$ 268.38万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 268.38万 - 项目类别:
Research Grant














{{item.name}}会员




